Novel LAG-3 Agonist Approach: Immutep's lead product, eftilagimod alpha (efti), is a first-in-class soluble LAG-3 fusion protein that acts as an MHC Class II agonist, differentiating it from traditional LAG-3 blocking antibodies and offering a unique mechanism to stimulate the immune system.

Versatile Combination Therapy Potential: Efti has demonstrated promising results in clinical trials when combined with other immunotherapies (like PD-1 inhibitors) and chemotherapy, suggesting broad applicability across various cancer types and treatment regimens.

Advanced Clinical Development & Data: The company's lead program, efti, is in advanced clinical stages (Phase 2/3), including a registrational trial for NSCLC (TACTI-003), backed by positive data indicating its efficacy and a favorable safety profile.